DK0951292T3 - Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde - Google Patents

Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde

Info

Publication number
DK0951292T3
DK0951292T3 DK97944453T DK97944453T DK0951292T3 DK 0951292 T3 DK0951292 T3 DK 0951292T3 DK 97944453 T DK97944453 T DK 97944453T DK 97944453 T DK97944453 T DK 97944453T DK 0951292 T3 DK0951292 T3 DK 0951292T3
Authority
DK
Denmark
Prior art keywords
subject
ischemic disorder
treating
sufficient
comprises administering
Prior art date
Application number
DK97944453T
Other languages
Danish (da)
English (en)
Inventor
David J Pinsky
David Stern
Ann Marie Schmidt
Eric A Rose
E Sander Connoly
Robert A Solomon
Charles J Prestigiacomo
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of DK0951292T3 publication Critical patent/DK0951292T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
DK97944453T 1996-09-27 1997-09-25 Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde DK0951292T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72144796A 1996-09-27 1996-09-27
PCT/US1997/017229 WO1998013058A1 (en) 1996-09-27 1997-09-25 Methods for treating an ischemic disorder and improving stroke outcome

Publications (1)

Publication Number Publication Date
DK0951292T3 true DK0951292T3 (da) 2007-08-13

Family

ID=24898028

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97944453T DK0951292T3 (da) 1996-09-27 1997-09-25 Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde

Country Status (10)

Country Link
EP (2) EP1829550A3 (enExample)
JP (1) JP2001501612A (enExample)
AT (1) ATE358492T1 (enExample)
AU (1) AU4594297A (enExample)
CA (1) CA2266640C (enExample)
DE (1) DE69737562T2 (enExample)
DK (1) DK0951292T3 (enExample)
ES (1) ES2285740T3 (enExample)
PT (1) PT951292E (enExample)
WO (1) WO1998013058A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712226A3 (en) * 1996-04-05 2007-03-21 The General Hospital Corporation Treatment of a Hemoglobinopathy
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
WO1999049803A1 (en) * 1998-04-01 1999-10-07 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
FR2816212A1 (fr) * 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
US20030198639A1 (en) * 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1404811B1 (en) 2001-06-21 2008-11-12 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
EP2042181A1 (en) 2002-02-04 2009-04-01 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
CA2475963A1 (en) * 2002-02-13 2003-09-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
ES2546280T3 (es) 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
EP1499328B1 (en) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
JP2005522521A (ja) 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
EP1505990B1 (en) 2002-05-17 2011-08-24 Yale University Methods of treating hepatitis
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
EP1684580A2 (en) * 2003-10-22 2006-08-02 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in tissues and organs
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
SI1934236T1 (sl) 2005-09-02 2013-02-28 Glycomimetics, Inc. Heterobifunkcionalni inhibitorji pan-selektina
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2010054393A1 (en) * 2008-11-10 2010-05-14 Mount Sinai School Of Medicine Of New York University Methods of inhibiting inflammation-associated tissue damage by inhibiting neutrophil activity
CN101732348B (zh) * 2008-11-11 2015-01-14 威世药业（如皋）有限公司 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
KR102055958B1 (ko) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
EP2842966B1 (en) * 2012-04-27 2018-08-15 Nihon University Therapeutic agent for epithelial and endothelial injury
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
PT3227310T (pt) 2014-12-03 2019-11-06 Glycomimetics Inc Inibidores heterobifuncionais de e-selectinas e recetores de quimiocina cxcr4
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CN109890421B (zh) 2016-10-07 2023-10-20 糖模拟物有限公司 高效的多聚体e-选择蛋白拮抗剂
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2019173229A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2022011247A1 (en) * 2020-07-10 2022-01-13 Children's Medical Center Corporation Targeted drug delivery to sites of intravascular occlusion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
DE69333447T2 (de) * 1992-05-22 2009-09-10 Montana State University, Bozeman Antikörper mit spezifikäten gegen mehrere adhäsionsmoleküle
US5591835A (en) * 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
CA2182215A1 (en) * 1994-01-28 1995-08-03 Reiji Kannagi Anti-inflammatory containing monoclonal antibodies having reactivity with sialyl-lewis x sugar chains originating in hemangioendothelial cell membrane
DE4403057C1 (de) * 1994-02-02 1994-12-08 Biotest Pharma Gmbh Thrombozytenstabilisierende Faktor IX-Fragmente, deren Herstellung sowie sie enthaltende Arzneimittel
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung

Also Published As

Publication number Publication date
EP0951292B1 (en) 2007-04-04
ES2285740T3 (es) 2007-11-16
DE69737562D1 (de) 2007-05-16
EP0951292A1 (en) 1999-10-27
PT951292E (pt) 2007-06-18
CA2266640A1 (en) 1998-04-02
WO1998013058A1 (en) 1998-04-02
CA2266640C (en) 2011-05-24
ATE358492T1 (de) 2007-04-15
EP1829550A3 (en) 2008-04-30
JP2001501612A (ja) 2001-02-06
DE69737562T2 (de) 2007-12-27
EP0951292A4 (en) 2004-08-04
AU4594297A (en) 1998-04-17
EP1829550A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
DK0951292T3 (da) Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
SG148850A1 (en) Methods of treating vascular disease
ATE481970T1 (de) Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
EA200401365A1 (ru) Способы лечения илеуса
NO963742L (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DK0739212T3 (da) Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
HU9701060D0 (en) Pharmaceutical composition for treating cognitive disturbs
EA199800535A1 (ru) Способ лечения боли
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
RU98122290A (ru) Способ лечения цервикокраниалгии при шейном остеохондрозе
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
ES2122236T3 (es) Sal de lisina de la 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida.
DK1019066T3 (da) Fremgangsmåder og præparater til forebyggelse og behandling af halsbrand
EE200100122A (et) R-(+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli kasutamine unehäirete raviks
ATE87614T1 (de) Methoden zur verwendung von 2-isopropyl-2phenylaminovaleriansaeurenitrilen als immunosupressoren und vasodilatoren.
EA199800818A1 (ru) Способ лечения бессонницы